When alterations in the EGFR subtypes were studied, it was found that EGFR alterations in exons 18–19 (five-year survival: 100%) represented better survival outcomes in resected NSCLC than those without such alterations (five-year survival: 47%) [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.